as adjunctive therapy to diet to reduce elevated levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, apolipoprotein (Apo) B, and triglycerides and to increase levels of high-density lipoprotein (HDL) cholesterol in adult patients with primary hyperlipidemia or mixed dyslipidemia. Pi...
Dyslipidemia, a major risk factor for cardiovascular diseases, has become a global issue. Due to the variations in the prevalence of dyslipidemia, this study aimed to evaluate dyslipidemia and its associated factors in women of the Bandare-Kong Cohort Study (BKNCD). This study was conducted on...
as adjunctive therapy to diet to reduce elevated levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, apolipoprotein (Apo) B, and triglycerides and to increase levels of high-density lipoprotein (HDL) cholesterol in adult patients with primary hyperlipidemia or mixed dyslipidemia. Pi...
The association between adverse lipid profiles in midlife and increased risk of late-life dementia has been well established,5 but whether dyslipidemia in older age is also associated with dementia remains uncertain. Recent studies have yielded inconsistent results, reporting increased, unchanged, and ...
What’s more, FMO3 knockdown in insulin-resistant mice could prevent hyperlipidemia and hyperglycemia via decreasing plasma TMAO [12]. The evidence above implies that TMAO might be a promising biomarker for diabetes-related diseases. However, to our best knowledge, there is no reported data ...
The prevalence of diabetes mellitus, hyperlipidemia and ischemic heart disease was 10.9%, 22.7% and 10.7%, respectively. The mean value of serum creatinine was 62.8 mmol lÀ1 (range 35.4–255.5 mmol lÀ1), and the frequency of eGFR o60 ml minÀ1 per 1.73 m2 was 16.5% (Figure 1c)...
Consistent with these mechanisms, ETC-1002 treatment reduced circulating proatherogenic lipoproteins, hepatic lipids, and body weight in a hamster model of hyperlipidemia, and it reduced body weight and improved glycemic control in a mouse model of diet-induced obesity. ETC-1002 offers promise as a...
proven coronary artery disease by coronary angiography or noninvasive tests, previous stroke, peripheral vascular disease, familial hyperlipidemia, pregnancy or oral contraceptive use, con- nective tissue disorders, neurological problems, malignancies, psychiatric diseases, smoking, alcohol use and drug ...
(HDL-c) in plasma compared to normal controls (p < 0.05). TPH or metformin alleviated dyslipidemia induced by the HFD. High concentrations of plasma leptin and TNF-α were found in MS rats and these were attenuated by TPH or metformin supplementation (p < 0.05; Data shown in ...
treatment of insulin resistance, hyperlipidemia and/or obesity or an overweight condition. the production of a medicament for the treatment and/or the prevention of an inflammatory disease or condition. The invention also relates to a compound according to formula (I) for the treatment and/or prev...